trial

Does tDCS Change Synaptic Density in the Brains of Patients With Schizophrenia

NCTId NCT05435300
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Recruiting
Enrollment 20 (estimated)
Sponsored by Centre for Addiction and Mental Health
Primary completion 2026-03-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
20 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2021-09-17
Primary completion
2026-03-31
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
PET Scan

Sponsors

Centre for Addiction and Mental HealthLead Sponsor

Investigators

1
Philip Gerretsen, MD, PhDPrincipal Investigator

Sites

1 total
Toronto, Canada

Facts & assertions

4 sourced
Enrollment
20
Phase
NA
Primary Completion Date
2026-03-31
Status
RECRUITING
relationships
The graph out of here
drug
PET Scan
drug
lead_sponsor
Centre for Addiction and Mental Health
company
indication
Schizophrenia
indication
Schizoaffective
indication
Schizophrenia
indication
investigator
Philip Gerretsen, MD, PhD
person